KCT0006066已完成未知
Dosage-randomized, double-blind, placebo-controlled, clinical trial to assess safety and tolerability after single or multiple oral administration of ES16001 in healthy volunteers
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- All
入选标准
- •1. Healthy adults aged 20 or older and 45 or younger at the time of screening test
- •- A person who has no congenital or treatment-related chronic disease and has no pathological symptoms or findings as a result of an internal examination;
- •- A person who is deemed suitable for clinical trials as a result of laboratory and ECG tests such as serum tests, hematologic tests, hemochemical tests, and urinary tests during screening tests
- •2. A person who weighs more than 55 kg at the time of screening and weighs less than ±20% of the ideal body weight.
- •* Ideal body weight = (height (cm) - 100) × 0.9)
- •3. A person who agrees not to donate sperm during the clinical trial period and up to three months after the end of the trial.
- •4. Persons identified as non-pregnant
- •5. A person who, after receiving a detailed explanation of this clinical trial, voluntarily decided to participate and agreed in writing to comply with the precautions
排除标准
- •1. A person with a medical history such as clinically significant and/or active cardiovascular, respiratory system, kidney, endocrine system, hematology, digestive system, central nervous system, mental illness, or malignancy
- •2. Persons with a history of gastrointestinal diseases (cron disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (except simple appendectomy or hernia surgery) that may affect the absorption of drugs for clinical trials
- •3. A person with a history of hypersensitivity reaction to any medications or additives for clinical trials
- •4. A person who is deemed inappropriate for the clinical trial through a medical examination (disease intensity, physical examination, vital signs, ECG examination, laboratory examination, etc.) conducted during screening.
- •5. A person who shows the following laboratory test results
- •- Hemoglobin < 13.0 g/dL
- •- 1.5 times the UNL of blood AST or ALT
- •- Total bilirubin > 1.5 times the upper limit
- •- 1.5 times the upper limit of CPK in blood
- •- MDRD (Modification of Diet in Renal Disease) < 60 mL/min/1.73 m2
- •6. A person identified as a chronic hepatitis B and hepatitis C carrier
- •7. After a break of more than 5 minutes, systolic blood pressure > 150 mmHg or <100 mmHg, and/or diastolic blood pressure >100 mmHg or <60 mmHg.
- •8. 12-lead ECG indicates QTcB interval greater than 450ms
- •9. A person who has a history of drug abuse or who has tested positive for a drug that may be misused
- •10. Excessive caffeine and alcohol intake, smokers (caffeine: >5 cups/day, alcohol: >210 g/week, tobacco: >10 pcs/day)
- •11. A person who has received a clinical trial drug within 180 days prior to the administration of a clinical trial drug
- •12. A person who has taken medication that induces and inhibits metabolic enzymes such as barbital drug within 30 days prior to administration of a clinical trial drug
- •13. A person who has donated whole blood within 60 days prior to administration of a clinical trial drug, or a person who has donated blood within 30 days prior to administration of a clinical trial drug, or who has received blood transfusion within 30 days
- •14. A person who has consumed grapefruit-containing food (e.g. > 1L or more grapefruit-containing beverages) within 14 days prior to administration of the clinical trial drug
- •15. A person who has taken a specialized medicine, herbal medicine, general medicine, or vitamin pill within 14 days prior to administration of a clinical trial drug
- •16. A person who determines that the tester is unfit to participate in a clinical trial due to other reasons
研究者
相似试验
尚未招募
不适用
A clinical trial that evaluates safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics after oral administration of investigational product(AVI-CO-004Tab) 10 days to male volunteers with AIDSCertain infectious and parasitic diseasesKCT0005329Avixgen36
已完成
不适用
Randomized, double-blind, placebo-controlled, dose-range study to assess the safety and efficacy of oral TAK-715 in the treatment of signs and symptoms of rheumatoid arthritis-M059M059PER-005-05TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
已完成
Unknown
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic properties of EB-203 eye drops in healthy adult volunteersDiseases of the eye and adnexaKCT0008881Eyebiokorea28
进行中（未招募）
不适用
Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.Pulmonary arterial hypertension (PAH) due to idiopathic pulmonary arterial hypertension (IPAH), familial PAH or PAH associated with connective tissue diseases (CTD) (e.g. systemic sclerosis, systemic lupus erythematosus) or to repaired congenital heart defects (RCHD).MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10065151Term: Idiopathic pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10065152Term: Familial pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10065150Term: Associated with pulmonary arterial hypertensionEUCTR2007-003621-24-NLMondoGEN AG48
进行中（未招募）
不适用
Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.EUCTR2007-003621-24-BEMondoGEN AG48